
A Cell Analysis Platform for Low-cost, Rapid Diagnosis of Sepsis Using Microfluidic TechnologiesAward last edited on: 3/30/2022
Sponsored Program
SBIRAwarding Agency
NSFTotal Award Amount
$1,604,605Award Phase
2Solicitation Topic Code
-----Principal Investigator
Mara MacdonaldCompany Information
CytoVale Inc (AKA: Cytometers)
150 Executive Park Boulevard Suite 4100
San Francisco, CA 94134
San Francisco, CA 94134
(562) 881-6919 |
info@cytovale.com |
www.cytovale.com |
Location: Single
Congr. District: 12
County: San Francisco
Congr. District: 12
County: San Francisco
Phase I
Contract Number: ----------Start Date: ---- Completed: ----
Phase I year
2013Phase I Amount
$184,998The broader impact/commercial potential of this project is realized by appreciating the applicability of the technology across research and clinical settings. Even without integration with fluorescence (flow) cytometry the technology has demonstrated its utility as a sensitive detector of malignancy in clinical specimens, specifically, pleural effusions. However, cell mechanics is an attractive biomarker for invasiveness, and is likely conserved throughout cells found in many biological fluids, including urine and fine needle aspirates. The proposed activity will further enhance the technology?s diagnostic accuracy. The instruments developed by Cytovale will be placed in clinical cytology labs to complement gold standard cytological methods, performing high sensitivity screens of biological fluids and eliminating unnecessary, invasive, and costly follow-up procedures. The hybrid instrument will also be an especially powerful tool for exploring connections between cell mechanics and traditional markers, which greatly extends the number of research laboratories which would benefit from this enabling technology.
Phase II
Contract Number: ----------Start Date: ---- Completed: ----
Phase II year
2015(last award dollars: 2017)